Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
national top stories
13
×
new york blog main
new york top stories
13
×
boston top stories
clinical trials
san francisco blog main
biotech
san francisco top stories
startups
fda
new york
san diego blog main
san diego top stories
amgen
deals
novartis
sanofi
vc
alnylam pharmaceuticals
biogen
boston
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
inclisiran
indiana blog main
indiana top stories
ipo
national
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
seattle blog main
seattle top stories
texas blog main
What
medicines
13
×
new
drug
fda
announced
ceo
cholesterol
deal
drugs
medco
research
aims
big
bio
biotech
covid
developing
field
genetic
ipo
lowering
medicine
morning
praxis
precision
roundup
startup
therapeutics
touting
twice
year
aces
acquire
acquisitions
activity
ago
agreed
aim
aiming
akcea
Language
unset
Current search:
medicines
×
" national top stories "
×
" new york top stories "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines